Amgen’s comments Thursday that it’s “very encouraged” by interim Phase 2 data for its obesity drug have quickly sparked immense investor interest in what could be a potential contender with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
The injectable drug MariTide, designed to be given monthly, could be a more attractive option than Wegovy and Zepbound, which are both dosed weekly. While the Phase 2 trial is still ongoing, Amgen is already planning to run a broad Phase 3 program and scale up manufacturing “with both clinical and commercial supply in mind,” Chief Executive Bob Bradway said on an earnings call.
advertisement
Even though executives shared no data from the interim analysis of its injectable drug, excitement around the molecule has already sent Amgen’s stock up 12% Friday.
Daratumumab plus a standard triplet improved minimal residual disease negativity rates in patients with transplant-ineligible multiple myeloma. The quadruplet also improved rates of complete response
Microplastics, which are minute plastic particles under 5mm in size, are becoming ever more ubiquitous in marine and freshwater ecosystems around the globe.
SAN DIEGO — Patients who engage in sexual activity and/or vaginal dilation after undergoing chemoradiation for cervical cancer had a lower risk of sexual health-related
4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor
Amgen’s comments Thursday that it’s “very encouraged” by interim Phase 2 data for its obesity drug have quickly sparked immense investor interest in what could be a potential contender with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
The injectable drug MariTide, designed to be given monthly, could be a more attractive option than Wegovy and Zepbound, which are both dosed weekly. While the Phase 2 trial is still ongoing, Amgen is already planning to run a broad Phase 3 program and scale up manufacturing “with both clinical and commercial supply in mind,” Chief Executive Bob Bradway said on an earnings call.
advertisement
Even though executives shared no data from the interim analysis of its injectable drug, excitement around the molecule has already sent Amgen’s stock up 12% Friday.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
View All Plans
Anti-CD38-Based Quadruplet Improves Outcomes in Transplant-Ineligible Myeloma
Daratumumab plus a standard triplet improved minimal residual disease negativity rates in patients with transplant-ineligible multiple myeloma. The quadruplet also improved rates of complete response
Microplastics as pathogen carriers in water pose environmental and public health risks
Microplastics, which are minute plastic particles under 5mm in size, are becoming ever more ubiquitous in marine and freshwater ecosystems around the globe.
Sexual Activity Lowers Risk of Side Effects After Cervical Cancer Treatment
SAN DIEGO — Patients who engage in sexual activity and/or vaginal dilation after undergoing chemoradiation for cervical cancer had a lower risk of sexual health-related